Abstract:BACKGROUND: Cancer immunotherapy has changed the standard of care for a subgroup of patients with advanced disease. Immune checkpoint blockade (ICB) in particular has shown improved survival compared with previous standards of care for several tumor types. Although proven to be successful in more immunogenic tumors, ICB is still largely ineffective in patients with tumors that are not infiltrated by immune cells, the so-called cold tumors.PATIENTS AND METHODS: This review describes the effects of different chemotherapeutic agents on the immune system and the potential value of these different types of chemotherapy as combination partners with ICB in patients with solid tumors. Both preclinical data and currently ongoing clinical trials were evaluated. In addition, we reviewed findings regarding different dosing schedules, including the effects of an induction phase and applying metronomic doses of chemotherapy.RESULTS: Combining ICB with other treatment modalities may lead to improved immunological conditions in the tumor microenvironment and could thereby enhance the antitumor immune response, even in tumor types that are so far unresponsive to ICB monotherapy. Chemotherapy, that was originally thought to be solely immunosuppressive, can exert immunomodulatory effects which may be beneficial in combination with immunotherapy. Each chemotherapeutic drug impacts the tumor microenvironment differently, and in order to determine the most suitable combination partners for ICB it is crucial to understand these mechanisms.CONCLUSION: Preclinical studies demonstrate that the majority of chemotherapeutic drugs has been shown to exert immunostimulatory effects, either by inhibiting immunosuppressive cells and/or activating effector cells, or by increasing immunogenicity and increasing T-cell infiltration. However, for certain chemotherapeutic agents timing, dose and sequence of administration of chemotherapeutic agents and ICB is important. Further studies should focus on determining the optimal drug combinations, sequence effects and optimal concentration-time profiles in representative preclinical models.

Immune-based combination therapy to convert immunologically cold tumors into hot tumors: an update and new insights

Overcoming cold tumors: a combination strategy of immune checkpoint inhibitors

Combinatorial regimens of chemotherapeutic agents: A new perspective on raising the heat of the tumor immune microenvironment

Immunotherapies catering to the unmet medical need of cold colorectal cancer

Combination strategies to maximize the benefits of cancer immunotherapy

Turning cold tumors into hot tumors by improving T-cell infiltration

Igniting Hope for Tumor Immunotherapy: Promoting the “Hot and Cold” Tumor Transition

Cold and hot tumors: from molecular mechanisms to targeted therapy

Immunologic tumor microenvironment modulators for turning cold tumors hot

Blockade of novel immune checkpoints and new therapeutic combinations to boost antitumor immunity

Improvement Strategy for Immune Checkpoint Blockade: A Focus on the Combination with Immunogenic Cell Death Inducers.

Recent Advances in Engineered Materials for Immunotherapy‐Involved Combination Cancer Therapy

Clinically approved combination immunotherapy: Current status, limitations, and future perspective

Combined Targeted Therapy and Immunotherapy for Cancer Treatment

Combining Immunotherapy and Radiotherapy for Cancer Treatment: Current Challenges and Future Directions

Strategies to enhance the therapeutic efficacy of anti-PD-1 antibody, anti-PD-L1 antibody and anti-CTLA-4 antibody in cancer therapy

Combination Cancer Immunotherapy Of Nanoparticle-Based Immunogenic Cell Death Inducers And Immune Checkpoint Inhibitors

Enhancing antitumor response by combining immune checkpoint inhibitors with chemotherapy in solid tumors

Anti-angiogenic Agents in Combination With Immune Checkpoint Inhibitors: A Promising Strategy for Cancer Treatment

Clinical application of immunogenic cell death inducers in cancer immunotherapy: turning cold tumors hot

Prospects for combining targeted and conventional cancer therapy with immunotherapy